n INTRODUCTION R esearch interest in vitamin D has increased over the past few years. In addition to the classic role of vitamin D on bone metabolism, leading to its use in the treatment of osteoporosis, many experimental data have underlined its pleiotropic effects on different tissues and cellular types, including those of the immune system (1) . Furthermore, several clinical studies report low vitamin D levels in association with an increase in cardiovascular risk (2) , development of cancer (3, 4) , and onset of autoimmune diseases (5) . As far as the immune system is concerned, many studies have shown the anti-inflammatory role of vitamin D through the modulation of both cellular proliferation and differentiation (6) . Recent studies focused on the association between hypovitaminosis D and the development of autoimmune diseases, both organ-specific (e.g. multiple sclerosis, diabetes mellitus type 1), and systemic diseases, e.g. systemic lupus erythematosus (SLE), rheumatoid arthritis (RA). Clinical studies have shown that hypovitaminosis D is very common in SLE patients (7) and low levels of vitamin D seem to be correlated with disease activity in RA (8) . Another study showed that patients with undifferentiated connective tissue disease (UCTD) and low levels of vitamin D were more likely to develop a well-defined autoimmune disease (9) . In our study, we considered patients with primary antiphospholipid syndrome (PAPS), a disease characterized by venous, arterial and small vessel thrombosis and/ or obstetric disease (fetal losses, prema-summary The aim of this study was to assess vitamin D (vit. D) levels in patients with primary antiphospholipid syndrome (PAPS), the association between hypovitaminosis D and clinical manifestations, and the effect of vit. D supplementation on serum levels. Vit. D serum levels of 115 PAPS patients, classified according to the 2006 revised criteria at the Rheumatology Department, Brescia, and of 128 voluntary healthy donors (NHD) were tested in collaboration with DiaSorin (Saluggia, Italy) using the LIAISON ® chemiluminescent immunoassay. Clinical data were derived from clinical charts. Vit. D deficiency was more prevalent in PAPS than NHD (17% vs 5%). During the summer, vit. D levels were lower in PAPS than NHD (median 28 vs 40.1 ng/mL, P<0.01). PAPS were subdivided according to clinical characteristics (thrombotic vs obstetric). Both groups had lower vit. D levels compared to NHD. Thrombotic PAPS had significantly lower levels than obstetric PAPS (median 20.8 vs 33.3, P<0.01). Sixteen patients (14%) received oral 25-OH vit. D supplementation (average 400 UI/die), but 63% of them did not reach serum levels above 30 ng/mL. PAPS showed significantly lower levels of vit. D than NHD. Hypovitaminosis D was seen to cluster in patients with thrombosis which may suggest that the lack of vit. D could be one of the many factors involved in the thrombotic process. Low-dose supplementation did not seem to be effective in a small group of patients. (14)). In all studies, the average value for PAPS patients was considered to be insufficient according to international guidelines (15) being below 30 ng/mL. Some of the limits of these studies include the lack of data on ethnicity, seasonality, nutrition and sun exposure; however, overall they do suggest that PAPS patients are affected by hypovitaminosis D just like patients with other systemic autoimmune diseases.
In the current study, we retrospectively analyzed a large cohort of PAPS patients for serum vitamin D levels, taking into consideration the factors that may influence vitamin D status. We also analyzed vitamin D levels according to different disease manifestations and the supplementation of patients with oral compound contain- original article (i.e. higher levels during summer) and significantly lower levels of vitamin D in PAPS (Fig. 1) . Likewise, the prevalence of deficiency (<10 ng/mL) was higher in the first group (17% vs 5%, Fisher's exact test P<0.05). A statistically significant differ- (19) are more predisposed to hypovitaminosis D. This is due to vitamin D sequestration into body fat and to the reduction in cutaneous 7-dehydrocholesterol, a vitamin D precursor, respectively. As already reported by our group (16), these environmental factors were taken into consideration in the evaluation of vitamin D levels in PAPS patients. Ethnicity and dietary habits were not confounding factors, since 96% of the patients were Caucasian and 97% were on an unrestricted diet. Furthermore, patients with PAPS did not require any long-term corticosteroid treatment or immunosuppressive therapy that could influence vitamin D levels (7) because they did not have any inflammatory organ involvement. We subdivided patients according to the season during which vitamin D levels were tested and compared them with healthy controls living in the same geographical area at different time points through the year. As controls, we considered 128 NHD with a median age that was lower than that of PAPS (34 vs 46 years) because blood donors are generally younger people. We found a great prevalence (64%) of vitamin D levels below 30 ng/mL among this healthy population, in line with epidemiological data in the literature (20) . Our data also showed that there was a seasonal variability in vitamin D levels (that are at their highest during the summer) and that there was no difference between women and men in vitamin D status. We showed that PAPS had lower levels than NHD, in particular during the summer. (21) showed that the risk of venous and arterial thrombosis was lower in patients who sunbathed and another study reported a reduction in the incidence of thrombotic events in cancer patients who were supplemented with calcitriol (22) . The type of compound (1,25-OH vitamin D vs 25-OH vitamin D) and the optimal dosage are the subject of discussion.
In our cohort, 14% of PAPS were supplemented over the short-term with treatment with steroid or heparin as a support to bone metabolism. In most of the patients, the low dose of vitamin D (average 400 UI/day) was not sufficient to enable levels to rise above 30 ng/mL. A similar observation was made in SLE patients who received an even higher dosage (800 UI/ day): 70% of subjects still had insufficient levels of vitamin D after supplementation (23) . According to these observations, it is plausible that higher doses of vitamin D may be required to significantly raise serum levels and possibly exert an immunological effect.
In conclusion, patients with PAPS have lower vitamin D levels than NHD, even if they do not have a full-blown disease such as SLE (therefore not requiring high steroid regimens or immunosuppressive therapies) and they do not have to limit their sun exposure in any particular way. The high prevalence of vitamin D insufficiency means that subjects with PAPS have more in common with patients with other systemic autoimmune diseases than with healthy subjects. These epidemiological data may suggest that vitamin D insufficiency can be one of the several factors that determine autoimmunity, rather than being an outcome of chronic disease and its treatment. In particular, this hypothesis may be supported by the observation that patients with thrombotic PAPS, a more aggressive phenotype, have greater vitamin D deficiency than those with pure obstetric disease. original article
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